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ABSTRACT
Introduction: Impetigo is the most common bacterial skin infection in children. Treatment is becoming
complicated due to the development of antimicrobial resistance, especially in the main pathogen,
Staphylococcus aureus. Ozenoxacin, a novel non-fluorinated topical quinolone antimicrobial, has
demonstrated efficacy in impetigo.
Areas covered: This article reviews the microbiology, pharmacodynamic and pharmacokinetic proper-
ties of ozenoxacin, and its clinical and microbiological efficacy in impetigo.
Expert opinion: In an environment of increasing antimicrobial resistance and concurrent slowdown in
antimicrobial development, the introduction of a new agent is a major event. Ozenoxacin is character-
ized by simultaneous affinity for DNA gyrase and topoisomerase IV, appears to be impervious to certain
efflux pumps that confer bacterial resistance to other quinolones, shows low selection of resistant
mutants, and has a mutant prevention concentration below its concentration in skin. These mechan-
isms protect ozenoxacin against development of resistance, while the absence of a fluorine atom in its
structure confers a better safety profile versus fluoroquinolones. In vitro studies have demonstrated
high potency of ozenoxacin against staphylococci and streptococci including resistant strains of
S. aureus. Clinical trials of ozenoxacin in patients with impetigo reported high clinical and microbiolo-
gical success rates. Preserving the activity and availability of ozenoxacin through antimicrobial steward-
ship is paramount.
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Impetigo is one of the most common bacterial skin infections
in children, particularly those aged two to five years [1–8].
Globally, the median prevalence of impetigo in the general
population is 11.2%, but is 2.5-fold higher in children (12.3%)
than adults (4.9%) [9], thus representing a high disease bur-
den, especially for children residing in low and low-middle
income countries or in socioeconomically disadvantaged
areas of high-income countries [9].
Impetigo lesions are typically located on the face, neck, and
hands, although scratching of pruritic lesions can transfer the
infection to other parts of the body and to close contacts. The
main causative pathogens of impetigo are Staphylococcus aur-
eus and Streptococcus pyogenes, both of which cause the non-
bullous form which occurs in around 70% of cases [7,10].
Bullous impetigo is caused exclusively by S. aureus due to
the production of exfoliative toxins [7,11].
The highly contagious nature of impetigo makes the con-
dition a particular concern for schools and day care centers
[1–4,7,8,10,12,13]. To limit the spread of infection, it is recom-
mended that children be kept at home until 24 h after the
start of appropriate antimicrobial therapy [14]. Disease con-
trol is also important to relieve symptoms (itching, sores),
minimize scarring due to scratching, and prevent rare but
serious complications such as rheumatic heart disease [15] or
glomerulonephritis [8].
Antimicrobial treatment of impetigo can produce a rapid
resolution of symptoms [10,13], thus limiting the risk of per-
son-to-person transmission. Clinical practice guidelines recom-
mend use of topical antibacterial agents for localized impetigo
and recommend use of oral antibiotics for patients with exten-
sive lesions unresponsive to topical therapy, for those with
systemic infection, and for managing outbreaks that affect
several people [16]. Topical antibacterial treatment delivers
a high concentration of drug directly to infected areas of
skin, facilitating the potential of the antimicrobial to overcome
bacterial resistance. Additionally, topical therapies are mini-
mally absorbed, which largely avoids the systemic side effects
associated with oral therapies [1]. Topical treatment has been
shown to be equally or more effective than oral therapy for
treating impetigo [13,16].
An increasing number of Gram-positive pathogens, especially
S. aureus, have developed resistance to topical antimicrobial
agents typically used in clinical practice. Antimicrobial resistance,
particularly methicillin-resistant S. aureus (MRSA) isolates, is
a major concern worldwide, and the emergence of community-
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acquired MRSA infections has aided the spread of resistant iso-
lates [17]. Fusidic acid resistance in S. aureus has emerged in
several countries, potentially limiting its overall efficacy [18–23].
Resistance has also been described to the commonly used topi-
cal agent mupirocin [24–27]. A recent large study of S. aureus
isolates (n = 358) from skin and soft tissue infection samples from
a mainly outpatient pediatric population found that 31.3% were
resistant to mupirocin [26]. Increasing rates of antimicrobial
resistance are a concern for patients with empirically managed
diseases such as impetigo [16] where treatment is often provided
without the benefits of microbial culture and/or susceptibility
testing results to guide appropriate care. Newer antimicrobial
agents with different modes of action to current drugs for impet-
igo, and with activity against resistant isolates, are clearly
desirable.
This review discusses the microbiological and pharmacoki-
netic properties of the novel non-fluorinated topical quino-
lone ozenoxacin and highlights new studies reporting its
therapeutic efficacy in impetigo.
2. Pharmacological properties
2.1. Mechanism of action
Quinolones act by inhibiting the enzymes DNA gyrase and
topoisomerase IV, both of which are involved in bacterial
DNA synthesis [28]. DNA gyrase catalyzes the negative super-
coiling of DNA, and thus plays an important role in the repli-
cation and transcription of DNA, and in organization of the
chromosome [29]. The main function of topoisomerase IV is to
decatenate the two daughter molecules of DNA after replica-
tion [30]. Both enzymes are tetrameric: DNA gyrase consists of
two A subunits (GyrA, encoded by the gyrA gene) and two
B subunits (GyrB, encoded by the gyrB gene); topoisomerase IV
also has two A subunits (ParC or GrlA, the latter in S. aureus,
encoded by the parC or grlA genes) and two B subunits (ParE
or GrlB, the latter in S. aureus, encoded by the parE or grlB
genes) [28]. Some quinolones (e.g. levofloxacin and ciproflox-
acin) act preferentially against topoisomerase IV over DNA
gyrase [31].
Ozenoxacin has been shown to inhibit DNA gyrase super-
coiling activity and topoisomerase IV decatenation simulta-
neously at the lowest concentrations in S. aureus SA113
compared with other quinolones [32]. This high inhibitory
activity of ozenoxacin at low concentrations might be
explained by its rapid penetration inside the bacterial cell in
the first minute after exposure and high intrabacterial concen-
trations compared with other quinolones in all studied micro-
organisms, among them S. aureus and S pyogenes, causal
agents of impetigo [33]. High accumulation of ozenoxacin
inside the Gram-positive bacterial cell may reflect its apparent
imperviousness to the activity of certain efflux pumps that
affect other quinolones [34].
The bactericidal capacity of ozenoxacin against S. aureus
and S. pyogenes compared to mupirocin and fusidic acid was
demonstrated in killing curves experiments [35]. In S. aureus,
ozenoxacin at two times the minimum inhibitory concentra-
tion (MIC) showed bactericidal activity by means of a 3-log
reduction in colony-forming units (CFU) after 4 h, whereas
mupirocin and fusidic acid at concentrations equivalent to
32 times the MIC showed bacteriostatic activity after 24 h
(Figure 1).
Collectively, the characteristics of ozenoxacin indicate
a high level of activity against Gram-positive bacteria [32–35].
2.2. In vitro antibacterial activity
In the most recent ozenoxacin surveillance study conducted
using isolates collected in 2014, the in vitro activity of ozenox-
acin was compared with other antimicrobial agents against
Gram-positive clinical isolates from skin and soft tissue infec-
tions [36]. A total of 1,031 isolates were collected from single
centers located in Spain, Argentina, Brazil, Colombia, Germany,
Romania, South Africa, Sweden, and two sites in the United
States (US). S. aureus isolates accounted for 49% of all isolates
collected. MICs were determined for 11 antimicrobial agents,
including topical agents such as mupirocin, fusidic acid, and
retapamulin. Isolates were stratified by species and by their
methicillin susceptibility/resistance and/or levofloxacin suscept-
ibility/nonsusceptibility status. Summary data for the six most
relevant comparators are shown in Table 1. Ozenoxacin showed
high in vitro activity against all S. aureus isolates, inhibiting
99.4% of isolates at a MIC of ≤0.05 mg/L. Ozenoxacin MIC50 and
MIC90 values were higher for levofloxacin-non-susceptible
S. aureus isolates (0.06 mg/L and 0.5 mg/L, respectively) than
for levofloxacin-susceptible S. aureus isolates (0.002 mg/L and
0.002 mg/L, respectively). Corresponding MIC values for levo-
floxacin were much higher for non-susceptible isolates (8 and
Article highlights
● Ozenoxacin is a novel non-fluorinated topical quinolone used for the
treatment of impetigo.
● Ozenoxacin simultaneously inhibits both enzymes responsible for
bacterial DNA replication and appears unaffected by the activity of
certain efflux pumps; this dual mechanism of antibacterial activity
affords protection from development of resistance.
● In vitro studies of the antibacterial activity of ozenoxacin showed
potency against staphylococci and streptococci including resistant
strains of Staphylococcus aureus.
● An in vivo study using a mouse model of S. aureus-induced dermal
infection showed superior efficacy of topical ozenoxacin 1% formula-
tions versus mupirocin 2% ointment and retapamulin 1% ointment,
as indicated by significant reductions in mean microbiological counts
in infected skin samples and superior bacterial eradication rates.
● Preclinical trials showed the absence of chondrotoxic potential with
ozenoxacin.
● Phase I studies showed that ozenoxacin has negligible transdermal
absorption and does not induce phototoxicity, photoallergy or con-
tact allergy.
● In two pivotal phase III studies of patients as young as 2 months with
impetigo, ozenoxacin 1% cream significantly improved clinical and
microbiological success rates compared with placebo (vehicle) cream
and was well tolerated.
● This review of preclinical and clinical data of ozenoxacin supports its
use for the treatment of impetigo.
● The role of ozenoxacin is likely to expand in future to include the
treatment of other skin and soft tissue infections.
● Antimicrobial stewardship is essential to protect this valuable
resource.
This box summarizes key points contained in the article.
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>16 mg/L, respectively) and were similar for susceptible isolates
(0.12 mg/L and 0.25 mg/L, respectively). Ozenoxacin was the
most potent agent tested against Staphylococcus epidermidis
isolates with MIC50 and MIC90 values of 0.008 and 0.25 mg/L,
respectively. Ozenoxacin inhibited 94.8% of S. epidermidis iso-
lates at a MIC of ≤0.05 mg/L. The activity of ozenoxacin was
higher against levofloxacin-susceptible versus levofloxacin-non-
susceptible S. epidermidis isolates, irrespective of their methicil-
lin resistance status. Ozenoxacin was the most potent agent
tested against S. pyogenes, inhibiting 98.3% of isolates at a MIC
of ≤0.03 mg/L, and against S. agalactiae, inhibiting 95.5% of
isolates at a MIC of ≤0.03 mg/L.
2.3. In vivo antibacterial activity
In a mouse model of S. aureus-induced dermal infection, oze-
noxacin (1% ointment and 1% cream formulations) signifi-
cantly reduced mean microbiological counts in infected skin
samples compared with mupirocin 2% ointment (positive con-
trol) and retapamulin 1% ointment (p < 0.05 for comparisons
of ozenoxacin formulations with mupirocin and retapamulin).
Bacterial eradication rates (relative log10 transformation of CFU
counts per gram of skin for control and test treatments) for
ozenoxacin 1% cream and 1% ointment were 53% and 47%,
respectively, compared with 31% for retapamulin and 28% for
mupirocin after a single application [37].
2.4. Resistance
Acquisition of quinolone resistance follows two main mechan-
isms. The first is through chromosomal mutations in bacterial
genes (gyrA, gyrB, parC, and parE) which encode the A and
B subunits of target proteins. The second is through mutations
which reduce accumulation of drug inside the cell, either by
decreased uptake (porin mutations) or increased efflux (over-
expression of efflux pumps) [38–40]. Quinolone resistance
genes associated with plasmids have been described in certain
Gram-negative bacteria [28]. In Gram-positive bacteria, the plas-
mid-mediated efflux pump QacB variant QacBIII was shown to
confer capability for fluoroquinolone efflux in S. aureus [41].
Elsewhere, however, and based on a low prevalence of the
plasmidic gene QacB in MRSA isolates and its absence in
methicillin-susceptible S. aureus isolates, investigators con-
cluded that QacBIII-mediated plasmidic mechanism of resis-
tance to quinolones is likely to be of low relevance, even in
quinolone-resistant MRSA strains [42]. Therefore, in Gram-
positive bacteria, quinolone resistance is associated mainly
with mutations in genes encoding GyrA and ParC and is com-
plemented by overexpression of some efflux pumps [28].
The development of quinolone resistance is caused by
point mutations in a specific region of the gyrA and parC
genes, called the Quinolone Resistance-Determining Regions
(QRDR). These genes encode the A subunit of DNA gyrase and
topoisomerase IV, respectively [43].
The activity of ozenoxacin was not influenced by mutations
in the grlA gene of S. aureus, and the degree of MIC increase
for ozenoxacin with gyrA-grlA double and triple mutants was
lowest among the quinolones tested (levofloxacin, nadifloxa-
cin, ofloxacin) [32]. In another in vitro study which compared
the antimicrobial activity of ozenoxacin, moxifloxacin, levoflox-
acin and ciprofloxacin on quinolone-susceptible and quino-
lone-resistant strains of S. aureus, ozenoxacin showed high
antimicrobial activity in methicillin-resistant strains, even
those with two, three, and/or four mutations in the gyrA
Figure 1. Bactericidal activity of ozenoxacin compared with mupirocin, fusidic acid and retapamulin against S. aureus ATCC 6538, evaluated by kill curves [35]. MBC:
minimal bactericidal concentration. MIC: minimal inhibitory concentration; CFU: colony-forming units; xMIC: number of times the MIC.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY 161
and/or grlA genes, and was not affected by the efflux pump
inhibitor reserpine [44].
As discussed previously, overexpression of some efflux
pumps can affect the MIC of some quinolones. In S. aureus,
the efflux pumps involved in quinolone resistance are NorA,
NorB, and NorC, belonging to the Major Facilitator Superfamily
(MFS) of proteins [45]. Another efflux pump involved in qui-
nolone resistance is MepA, which belongs to the Multiple
Antibiotic and Toxin Extrusion (MATE) family of proteins
[28,45]. In a recent study which tested several S. aureus strains
presenting overproduction of some efflux pumps (e.g. NorA
and MepA) against ozenoxacin, moxifloxacin, levofloxacin,
ciprofloxacin and norfloxacin, the MICs of ozenoxacin were
considerably lower than those for the other quinolones and
were unaffected in strains with overexpression of these efflux
pumps [34].
For some antibiotics, of which fluoroquinolones are probably
the paradigm, it has been established that resistant mutants are
selected in the so-called ‘mutant selection window’, which is the
concentration range starting from the MIC to that required to
inhibit the growth of the least susceptible single-step mutant.
The upper boundary of the mutant selection window is also
known as the mutant prevention concentration (MPC). The
antibiotic concentration at a site of infection must always be
maintained above the MPC to prevent generation of resistant
mutants and to eradicate any growing resistant subpopulations
[46–48]. The MPC of ozenoxacin determined in strains of methi-
cillin-susceptible S. aureus, either wild-type or with a single
mutation in the gyrA and/or parC genes, ranged from 0.05 to
1.2 mg/L, and that for methicillin-resistant S. aureus was 0.6 mg/
L for strains with a mutation in the amino acid codon Ser-83 of
the gyrA gene [49].
A single topical application of ozenoxacin cream delivers
approximately 5 mg of active ingredient to the skin. Gropper
and colleagues reported a mean ozenoxacin concentration of
~22,000 ng/mg (22 mg/L) in the stratum corneum (tape strip-
ping samples) in human volunteers after twice daily adminis-
tration of ozenoxacin cream for 3 days [50]. These
concentrations are markedly higher than the predicted MIC
of ozenoxacin (MIC range 0.008–0.25 mg/L) [36] and predicted
MPC values for common impetigo pathogens including resis-
tant strains of S. aureus [49].
Ozenoxacin has shown no cross-resistance with other
families of commercial antibacterial agents against Gram-
positive organisms and retains its activity below breakpoints
for mutant species resistant to other marketed quinolones
[36]. Ozenoxacin showed the same level of activity against
Table 1. In vitro activity of ozenoxacin and comparators against worldwide
isolates of S. aureus, S. epidermidis, S. pyogenes, and S. agalactiae from skin











S. aureus (all) (504) Ozenoxacin ≤0.001–2 0.002 0.06
Mupirocin 0.06–>256 0.25 0.5
Fusidic acid ≤0.015–>16 0.12 0.25
Retapamulin 0.03–>1 0.12 0.12
Levofloxacin 0.06–>16 0.25 16
Ciprofloxacin 0.12–>16 0.25 >16
MSSA (279) Ozenoxacin ≤0.001–0.25 0.002 0.004
Mupirocin 0.06–>256 0.25 0.5
Fusidic acid ≤0.015–>16 0.12 0.25
Retapamulin 0.03–>1 0.12 0.25
Levofloxacin 0.06–>16 0.12 0.25
Ciprofloxacin 0.12–>16 0.25 1
MRSA (225) Ozenoxacin ≤0.001–2 0.004 0.12
Mupirocin 0.06–>256 0.25 0.5
Fusidic acid 0.06–>16 0.12 0.25
Retapamulin 0.03–>1 0.12 0.12
Levofloxacin 0.06–>16 0.25 >16
Ciprofloxacin 0.12–>16 0.5 >16
Levofloxacin-susceptible
S. aureus(383)
Ozenoxacin ≤0.001–0.03 0.002 0.002
Mupirocin 0.06–>256 0.25 0.25
Fusidic acid 0.03–>16 0.12 0.25
Retapamulin 0.03–>1 0.12 0.25
Levofloxacin 0.06–1 0.12 0.25




Ozenoxacin 0.008–2 0.06 0.5
Mupirocin 0.06–>256 0.25 2
Fusidic acid ≤0.015–>16 0.12 0.25
Retapamulin 0.03–0.25 0.12 0.12
Levofloxacin 2–>16 8 >16
Ciprofloxacin 4–>16 >16 >16
S. epidermidis (all) (195) Ozenoxacin ≤0.001–2 0.008 0.25
Mupirocin 0.06–>256 0.25 >256
Fusidic acid 0.06–>16 0.12 8
Retapamulin 0.03–>1 0.06 0.25
Levofloxacin 0.12–>16 0.25 >16
Ciprofloxacin 0.06–>16 0.5 >16
Methicillin susceptible
S. epidermidis (MSSE) (86)
Ozenoxacin ≤0.001–2 0.004 0.03
Mupirocin 0.06–>256 0.25 256
Fusidic acid 0.06–>16 0.12 8
Retapamulin 0.03–>1 0.06 0.25
Levofloxacin 0.12–>16 0.25 4




Ozenoxacin 0.002–2 0.06 0.5
Mupirocin 0.06–>256 0.25 >256
Fusidic acid 0.06–>16 0.12 16
Retapamulin 0.03–>1 0.06 0.12
Levofloxacin 0.12–>16 4 >16
Ciprofloxacin 0.12–>16 8 >16
Levofloxacin-susceptible
S. epidermidis (105)
Ozenoxacin ≤0.001–0.015 0.004 0.008
Mupirocin 0.06–>256 0.25 >256
Fusidic acid 0.06–>16 0.12 4
Retapamulin 0.03–>1 0.06 0.25
Levofloxacin 0.12–0.5 0.25 0.25
Ciprofloxacin 0.06–1 0.25 0.5
Levofloxacin-non-susceptible
S. epidermidis (90)
Ozenoxacin 0.008–2 0.06 1
Mupirocin 0.06–>256 0.25 >256
Fusidic acid 0.06–>16 0.12 16
Retapamulin 0.03–>1 0.06 0.12
Levofloxacin 2–>16 8 >16
Ciprofloxacin 2–>16 >16 >16
Streptococcus pyogenes
(124)
Ozenoxacin ≤0.001–0.25 0.008 0.015
Mupirocin ≤0.015–0.5 0.06 0.25
Fusidic acid ≤0.015–>16 4 4
Retapamulin ≤0.015–0.25 0.03 0.06
Levofloxacin ≤0.015–2 0.5 1















Ozenoxacin 0.002–0.5 0.015 0.03
Mupirocin 0.5–8 1 1
Fusidic acid 4–16 8 16
Retapamulin 0.03–0.5 0.06 0.12
Levofloxacin 0.25–>16 0.5 1
Ciprofloxacin 0.25–>16 0.5 1
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methicillin-susceptible and methicillin-resistant strains of all
studied bacterial species [36].
3. Pharmacokinetic properties
3.1. Absorption
Analysis of tape stripping samples and skin punch biopsy
samples following topical application of ozenoxacin 2%
cream to healthy volunteers (n = 24) showed that ozenoxacin
does not penetrate the skin. Ozenoxacin concentrations were
high in the stratum corneum, low in the epidermis, and below
the limit of quantitation in the dermis on most study days [50].
Clinical pharmacokinetic phase I studies conducted in
healthy adult volunteers (n = 84) [51] and subjects with impet-
igo (aged 2 months to 65 years; n = 46) [52] found no or
negligible systemic absorption following repeated topical
application of varying strengths (1% or 2%) of ozenoxacin
cream or ointment to intact or abraded skin [53]. Ozenoxacin
plasma concentrations above the lower limit of quantification
(0.5 ng/mL) were found in two children treated with ozenox-
acin 1% cream for impetigo, with respective values of 0.539
and 0.681 ng/mL [52].
3.2. Distribution, metabolism, and elimination
As either no or negligible systemic absorption of ozenoxacin
was observed in phase I clinical studies [51,52], the tissue
distribution, metabolism and elimination of ozenoxacin in
humans have not been investigated.
4. Therapeutic efficacy
4.1. Clinical efficacy
The efficacy and safety of ozenoxacin 1% cream in the treatment
of impetigo have been demonstrated in two pivotal placebo-
controlled phase III clinical trials [54,55]. In both studies, placebo
consisted of cream vehicle without the active ingredient ozenox-
acin. The vehicle contains benzoic acid among other excipients.
The first randomized, double-blind, multicenter phase III
study compared ozenoxacin 1% cream (n = 155) with placebo
(vehicle) cream (n = 156) in adults and children aged >2 years
with impetigo [54]. The study included a retapamulin 1% oint-
ment arm (n = 154) for internal validation. Study drug was
applied twice daily for 5 days and clinical, microbiological and
laboratory evaluations were performed over a 2-week follow-up.
Total affected area (mean ± standard deviation [SD]) was
9.34 ± 16.73 cm2, 12.85 ± 21.40 cm2, and 12.12 ± 22.51 cm2 for
ozenoxacin, placebo, and retapamulin, respectively. Analysis of
the primary efficacy endpoint, the clinical success rate (i.e. clinical
cure) in the intention-to-treat (ITT) population at the end of
therapy (day 6–7), demonstrated that ozenoxacin was signifi-
cantly superior to placebo (34.8 vs. 19.2%, p = 0.003). The internal
control retapamulin was also superior to placebo (37.7 vs. 19.2%,
p < 0.001). In this study, clinical success was determined by
means of the Skin Infection Rating Scale (SIRS), similar to that
used in phase III retapamulin trials, which assesses seven signs/
symptoms scored from 0 (absent) to 6 (severe). As clinical success
rates reported for other marketed topical antibiotics include
both clinical cure and improvement, a post hoc analysis was
performed to obtain comparable efficacy results. Ozenoxacin
was again superior to placebo in this analysis (85.2 vs. 73.7%;
p = 0.028), and the results compare favorably with clinical suc-
cess rates from randomized controlled trials of other topical
antibiotics versus placebo: 68–82% vs. 29–42% for mupirocin
(1980s); 55 vs. 13% for fusidic acid (2003); and 85 vs. 52% for
retapamulin (2006) [13].
In the second randomized, double-blind, phase III study,
patients aged 2 months and older with impetigo were rando-
mized to receive topical ozenoxacin 1% cream (n = 206) or
placebo (vehicle) cream (n = 206) twice daily for 5 days [55].
Total affected area (mean ± SD) was 10.29 ± 13.04 cm2 and
8.84 ± 8.12 cm2 for ozenoxacin and placebo, respectively. In this
study, the primary efficacy outcome of clinical response (clinical
cure) in the ITT population at the end of therapy was based on
SIRS scores for five signs/symptoms, scored from 0 (absent) to 3
(severe) as per recommendations of the FDA Draft Guidance on
mupirocin [56]. Ozenoxacin was significantly superior to pla-
cebo, with clinical success rates of 54.4% and 37.9%, respec-
tively, at the end of 5 days’ therapy (p = 0.001). A secondary
outcome was clinical success inclusive of clinical cure and
improvement. In this analysis, 88.8% of patients in the ozenox-
acin group achieved clinical success at the end of therapy
compared to 78.2% in the placebo group (p = 0.003).
A subsequent pooled analysis of individual patient data
from both phase III trials in patients with impetigo treated
with ozenoxacin (n = 361) or placebo (n = 362) confirmed the
superior efficacy of ozenoxacin [57]. Clinical success rates in
the ITT population at the end of therapy were 47.3% and
31.4%, respectively (p < 0.001). The proportion of subjects
achieving clinical success at the end of therapy, inclusive of
clinical cure and improvement, also significantly favored oze-
noxacin (p < 0.0001; Figure 2).
4.2. Microbiological efficacy
The phase III clinical trials also evaluated the microbiological
efficacy of ozenoxacin 1% cream and comparators [54,55].
Microbiological responses were assessed following culture of
specimens taken from baseline affected area(s) at all study
visits if culturable material was present. Since S. aureus and
S. pyogenes alone or in combination are responsible for the
majority of cases of impetigo, other microorganisms were
considered as pathogens only if neither of these two bacter-
ium was identified at baseline [58].
In the first phase III trial in patients aged 2 years and older,
microbiological clearance rates were significantly higher with
ozenoxacin than placebo [54]. Respective microbiological suc-
cess rates were 70.8% and 38.2% (p < 0.0001) after 2–3 days’
treatment, and 79.2% and 56.6% (p < 0.0001) at the end of
treatment (days 6–7). Compared with retapamulin, microbio-
logical clearance rates with ozenoxacin were higher after
2–3 days’ treatment (70.8 vs. 56.9%; p = 0.0087) and compar-
able after 5–6 days’ treatment (79.2 vs. 81.7%; p = 1.000).
Similarly, in the second phase III trial in patients aged
2 months and older, microbiological clearance rates were
significantly greater with ozenoxacin than placebo [55].
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Microbiological success rates reported in the ozenoxacin and
placebo groups were 87.2% and 63.9% (p = 0.002), respec-
tively, after 2–3 days of therapy, and 92.0% and 73.1%
(p = 0.005), respectively, after 5 days’ therapy.
Pooled analysis of data from both phase III trials indicated
that microbiological success rates were significantly higher
with ozenoxacin (n = 279) than placebo (n = 271) after
2–3 days of therapy and at the end of therapy (both
p < 0.0001; Figure 3) [57]. Available culture-based pooled
microbiologic data suggested superior early eradication of
bacterial etiology in the ozenoxacin versus placebo group.
Eradication + presumed eradication rates of S. aureus with
ozenoxacin and placebo were 86.6% and 50%, respectively,
after 2–3 days’ therapy, and 75.8% and 39.5% at the end of
treatment. Corresponding figures for S. pyogenes were 75.8%
and 39.5% after 2–3 days’ therapy, and 87.9% and 60.4% at the
end of treatment [58].
4.3. Activity against antimicrobial-resistant strains
In the pooled analysis of phase III trials, S. aureus strains
showing demonstrable resistance to at least one of the anti-
bacterial agents tested, i.e. methicillin (oxacillin), ciprofloxa-
cin, retapamulin, mupirocin, and fusidic acid, were identified
in 36 ozenoxacin-treated patients at baseline; two patients
had S. pyogenes strains resistant to at least one of these
antibacterial agents [57]. All patients with resistant infections
achieved clinical cure or improvement at the end of treat-
ment, including 11 of 11 patients with mupirocin-resistant
S. aureus, and 10 of 10 patients with methicillin-resistant
S. aureus. Of 23 ciprofloxacin-resistant S. aureus strains trea-
ted with ozenoxacin, two were microbiologic failures
although, in both cases, the clinical result was improvement;
thus, all patients achieved clinical improvement or cure at
the end of treatment.
Ozenoxacin demonstrated similar clinical and microbiologi-
cal success rates irrespective of the presence of the virulence
genes Panton–Valentine leukocidin (PVL) and phenol-soluble
modulin (PSM) [59] in S. aureus isolates [57].
5. Safety
Molecular modifications to moieties on the basic quinolone
pharmacophore, specifically the addition of fluorine at posi-
tion 6 and other substitutions at positions 1, 5, 7 and 8, led to
development of a series of fluoroquinolone compounds with
enhanced antibacterial efficacy and superior pharmacokinetic
characteristics [60,61]. However, a relationship exists between
specific structural alterations and adverse effects observed
with individual agents [60,61]. Ozenoxacin, in contrast, has
no fluoride substituent at the C-6 position and is devoid of
halogen substituents in other positions [32]. As such, ozenox-
acin is expected to have a better safety profile relative to other
quinolones.
As quinolones have recognized chondrotoxic effects in juve-
nile animals, preclinical studies were conducted to assess the
potential toxicity of ozenoxacin [62]. Typical quinolone-induced
articular cartilage lesions with chondromucinous degeneration
were observed in 3 of 10 juvenile rats treated with oral oflox-
acin, whereas no histopathological toxicologically relevant
changes were observed in the group treated with ozenoxacin.
Likewise, in juvenile dogs, oral administration of ozenoxacin for
14 days was not associated with any chondrotoxicity or toxico-
logically relevant findings in selected target organs (brain, thy-
mus, lung, liver, and kidney).
As part of the ozenoxacin clinical development program,
a series of randomized placebo-controlled phase I studies
using industry methods were conducted in healthy adult volun-
teers to assess its potential to cause local toxicity under occlusive
patch conditions [63]. Ozenoxacin 1% and 2% cream formula-
tions both showed excellent dermal tolerability. Across eight
studies, there was little to no evidence of cumulative irritation,
sensitizing potential, phototoxicity or photoallergy. Almost all
adverse events reported in repeated-dose studies were deemed
unlikely to be related or unrelated to ozenoxacin application.
Figure 2. Clinical success rate at the end of treatment (day 6–7) in a pooled analysis of phase III studies of ozenoxacin 1% cream versus placebo (vehicle) cream.
Clinical success was defined as clinical cure or improvement. The clinical success rate for the internal control retapamulin was 84.2% [57].
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Of 875 patients who participated in phase III clinical trials of
ozenoxacin [57], a single adult patient (<0.1%) receiving oze-
noxacin had two adverse events (worsening of pre-existing
rosacea and seborrheic dermatitis) which were considered pos-
sibly or probably related to treatment. Placebo-related events
were dermatitis and skin tightness, and events related to reta-
pamulin 1% ointment were application site pain and urticaria.
As no treatment-related adverse event occurred in more than
one subject, no patterns or safety signals were identified.
6. Dosage and administration
Topical ozenoxacin 1% cream is indicated in the European
Union for short-term treatment of non-bullous impetigo in
adults, adolescents, children and infants aged 6 months and
older [64], and in the US and Canada for treatment of impet-
igo due to S. aureus or S. pyogenes in adult and pediatric
patients 2 months of age and older [65,66]. No dosage adjust-
ments are required in patients with renal or hepatic impair-
ment, or in elderly patients [64].
The approved posology and method of administration of
ozenoxacin is to apply a thin layer of ozenoxacin 1% cream
(10 mg/g) to the affected area twice daily for 5 days. The affected
area may be up to 100 cm2 in adult and pediatric patients
12 years of age and older, or up to 2% of the total body surface
area and not exceeding 100 cm2 in pediatric patients less than
12 years of age [64–66]. The treated area may be covered by
a sterile bandage or gauze dressing as desired [64–66].
Since systemic exposure to ozenoxacin is negligible, no
effects are anticipated during pregnancy. Whether ozenoxacin
is excreted in human breast milk is unknown; however, due to
the minimal systemic exposure observed in adults, exposure of
a breastfeeding infant to ozenoxacin is likely to be negligible.
Nevertheless, it is recommended to avoid applying ozenoxacin
to the breast area during breastfeeding to protect the nursing
infant from unintentional oral drug uptake [64–66].
7. Expert opinion
The ability to treat infectious diseases is under serious threat
due to the emergence and global spread of antibiotic resis-
tance. The situation is intensified by a simultaneous decline in
the development of new antimicrobial agents, severely limit-
ing the options available to treat increasingly resistant infec-
tions [67]. Development and introduction of a new antibiotic is
thus a significant event, and responsible management of anti-
microbials by health-care professionals to preserve their use in
future is of paramount importance [68].
Ozenoxacin is a novel non-fluorinated topical quinolone
approved for treatment of impetigo due to S. aureus or
S. pyogenes. The characteristics of ozenoxacin set it apart from
other members of the quinolone family. Whereas most quino-
lones act by binding irreversibly to either DNA gyrase or topoi-
somerase IV in the bacterial cell, ozenoxacin has simultaneous
affinity for both enzymes. Ozenoxacin also appears to be unaf-
fected by the activity of certain efflux pumps which commonly
confer bacterial resistance to other quinolones. As a result, oze-
noxacin accumulates inside the bacteria much more quickly and
at higher concentrations compared with other quinolones.
Ozenoxacin shows low selection of resistant mutants and has
a MPC below the concentration it achieves in skin. Collectively,
these properties reduce the susceptibility of ozenoxacin to resis-
tance development. The absence of a fluorine atom at position 6
of its molecular structure affords ozenoxacin a more favorable
safety profile than fluorinated quinolones.
Antibiotics with a rapid bactericidal effect are important for
symptoms resolution. This is especially relevant in the pediatric
setting to limit person-to-person transmission of infection. In
Figure 3. Microbiological success rates at the second visit (day 2-3) and at the end of treatment (day 6–7) in a pooled analysis of phase III studies of ozenoxacin 1%
cream versus placebo (vehicle) cream. Microbiological success was defined as microbial eradication [57].
Blue=Ozenoxacin; Grey=Placeblo.
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vitro studies which compared the activity of ozenoxacin with an
extensive range of other antimicrobial agents against Gram-
positive clinical isolates from skin and soft tissue infections
demonstrated that ozenoxacinwas themost potent agent tested
against staphylococci and streptococci. Ozenoxacin susceptibil-
ity studies were conducted using the ISO standard broth micro-
dilution technique as per European Committee on Antimicrobial
Susceptibility Testing (EUCAST) and Clinical & Laboratory
Standards Institute (CLSI) guidance; breakpoints have yet to be
defined by EUCAST or CLSI. Ozenoxacin was shown to be bacter-
icidal against methicillin-susceptible S. aureus, methicillin-
resistant S. aureus, methicillin-susceptible S. epidermidis, and
methicillin-resistant S. epidermidis – including levofloxacin-
susceptible and levofloxacin-resistant isolates – as well as against
S. pyogenes, and S. agalactiae. Clinical trials of ozenoxacin in
patients with impetigo demonstrated high clinical and microbio-
logical success rates as early as two days after initiation of
therapy, including in patients with mupirocin-resistant or methi-
cillin-resistant S. aureus. Culture-based data indicated early era-
dication rates 1.7 and 1.9-fold higher with ozenoxacin than
placebo for S. aureus and S. pyogenes, respectively, the major
pathogens implicated in impetigo.
In view of the emerging resistance to fusidic acid and
mupirocin, ozenoxacin represents a valuable addition to the
antibacterial arsenal for treating impetigo and deserves to be
treated as such. Use of ozenoxacin may decrease numbers of
circulating mupirocin-resistant or methicillin-resistant isolates.
An antimicrobial agent such as ozenoxacin with inherent
defenses against the development of resistance is a valuable
commodity that must be protected for future generations.
Antimicrobial stewardship is essential to optimize the use of
ozenoxacin and improve patient outcomes now and in future.
8. Five-year view
Over the next few years, it is expected that clinical practice guide-
lines for managing impetigo will be updated to include recom-
mendations about the use of ozenoxacin. Further studies will be
conducted to follow up on antimicrobial resistance patterns and
the impact of ozenoxacin in quinolone resistance as well asmupir-
ocin andmethicillin resistance. Importantly, even with greater use
of ozenoxacin to treat impetigo, no increase in ozenoxacin-
resistant strains is expected on account of its dual mechanism of
antibacterial activity and low potential to select resistant mutants.
In future, the role of ozenoxacin is likely to expand to include
treatment of other types of skin and soft tissue infections.
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